Gonzalo Vina - AstraZeneca PLC Head Relations
| AZNCF Stock | USD 125.50 0.80 0.64% |
Insider
Gonzalo Vina is Head Relations of AstraZeneca PLC
| Phone | 44 20 3749 5000 |
| Web | https://www.astrazeneca.com |
AstraZeneca PLC Management Efficiency
The company has return on total asset (ROA) of 0.0531 % which means that it generated a profit of $0.0531 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0863 %, meaning that it generated $0.0863 on every $100 dollars invested by stockholders. AstraZeneca PLC's management efficiency ratios could be used to measure how well AstraZeneca PLC manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Laurie Babinski | IONQ Inc | 42 | |
| David Denton | Pfizer Inc | 59 | |
| Thomas Kramer | IONQ Inc | 53 | |
| John Varner | Genprex | 67 | |
| Laura Sayavedra | Enbridge | 57 | |
| Shobie Ramakrishnan | GSK plc | N/A | |
| Amie OToole | Alphabet Inc Class C | 49 | |
| William Carapezzi | Pfizer Inc | 63 | |
| Sarah EltonFarr | GSK plc | N/A | |
| Diana Conrad | GSK plc | N/A | |
| Mike Mcdermott | Pfizer Inc | N/A | |
| William Gray | Pfizer Inc | N/A | |
| Michael Mcdermott | Pfizer Inc | 55 | |
| Patrick Murray | Enbridge | 48 | |
| Tom Jones | IONQ Inc | N/A | |
| Noam Zakay | IONQ Inc | N/A | |
| Kent Walker | Alphabet Inc Class C | 63 | |
| Maria Llano | Grifols SA ADR | 59 | |
| Allan Evans | Red Cat Holdings | 40 | |
| V Darkes | Enbridge | 71 | |
| Guardie Banister | Enbridge | 63 | |
Management Performance
| Return On Equity | 0.0863 | |||
| Return On Asset | 0.0531 |
AstraZeneca PLC Leadership Team
Elected by the shareholders, the AstraZeneca PLC's board of directors comprises two types of representatives: AstraZeneca PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AstraZeneca. The board's role is to monitor AstraZeneca PLC's management team and ensure that shareholders' interests are well served. AstraZeneca PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AstraZeneca PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marc Dunoyer, CFO and Executive Director | ||
| Chris Sheldon, Head Relations | ||
| Pam Cheng, Executive Vice-President of Operations and Information Technology | ||
| MBA DVM, CEO Director | ||
| Gonzalo Vina, Head Relations | ||
| Aradhana MD, CFO Director | ||
| Menelas Pangalos, Executive Vice President - Innovative Medicines | ||
| Katarina Ageborg, Chief Compliance Officer | ||
| Jeffrey Pott, General Counsel | ||
| Ruud Dobber, Executive Vice President Europe |
AstraZeneca Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is AstraZeneca PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0863 | |||
| Return On Asset | 0.0531 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 241.1 B | |||
| Shares Outstanding | 1.55 B | |||
| Shares Owned By Insiders | 0.22 % | |||
| Shares Owned By Institutions | 48.84 % | |||
| Price To Earning | 44.18 X | |||
| Price To Book | 6.16 X |
Currently Active Assets on Macroaxis
Other Information on Investing in AstraZeneca Pink Sheet
AstraZeneca PLC financial ratios help investors to determine whether AstraZeneca Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AstraZeneca with respect to the benefits of owning AstraZeneca PLC security.